National Cancer Institute; Amended Notice of Meeting, 24166 [2019-10943]
Download as PDF
<![CDATA[
khammond on DSKBBV9HB2PROD with NOTICES
24166
Federal Register / Vol. 84, No. 101 / Friday, May 24, 2019 / Notices
‘‘CSC × 24 hrs’’ to represent Skp2
protein expression in CTCL Patients
➢ Six band images from Figure 5B in a
paper published in Biochemistry 1 to
represent Actin protein expression in
eight (8) CTCL Patients, one (1) T–
ALL Patient, and two (2) normal
subjects in Figure 1 of JCI 2011 and
Figure 3 (bottom panel) in R01
CA122737–01A2
• In Figure 8B (bottom part) in JCI
2011, also included as Figure 9 in R01
CA122737–01A2 and Slide 29 in the
CREST Presentation, respondent falsely
reused b-actin, Laminin B, alphatubulin, GFP-Pro-IL–16 and HSC70
band images of ‘‘Knockdown of HSC70
in Jurkat cells and Hut78 cells’’ as from
Normal Human Patient and Normal
Subject T-cells.
• In Figure 14A in R01 CA122737–
01A2, respondent falsely reused GFPPro-IL–16 band images of ‘‘Knockdown
of HSC70 in Jurkat cells’’ as AKT and
phospho-AKT expression and the
nuclear Pro-IL–16 band images from
Figure 5B in Biochemistry 2002 as
FOXO1 protein expression in human Tcells stimulated with IL–16.
• In Figure 14B in R01 CA122737–
01A1 and R01 CA122737–01A2,
respondent falsely reused band images
from Figure 5B in Biochemistry 2002
that represents Anti-pro IL6 and AntiTubulin to represent FOXO1 protein
expression in human T-cells.
• In Figure 9 in JCI 2011, respondent
falsely reused band images representing
CD26–T cells of CTCL Patient to also
represent normal human subject control
for CD26+ and control for CD26–T cells
in the same figure.
• In Figure 5 in R01 CA122737–01A1,
also included as Figure 4 in R01
CA122737–01A2, respondent reused
and falsely relabeled band images
within the same figure to represent
different experimental conditions.
Respondent intentionally, knowingly,
and recklessly falsified and/or
fabricated Western blot data for siRNA
knockdown of Heat shock cognate 71
kDa protein (HSC70) in Jurkat cells
purportedly with two different siRNA
constructs, by reusing and relabeling ten
(10) band images from experiments on
Hut78 cells and a failed experiment in
Jurkat cells, and included them in four
(4) figures in one manuscript, one
published paper, one grant application,
and one presentation.
Specifically, respondent reused band
images of an unpublished Western blot
figure, by:
1 Wilson KC, Cruikshank WW, Center DM, Zhang
Y. Prointerleukin-16 contains a functional CcN
motif that regulates nuclear localization.
Biochemistry 2002;41:14306–14312 (hereafter
referred to as ‘‘Biochemistry 2002’’).
VerDate Sep<11>2014
18:10 May 23, 2019
Jkt 247001
• Reusing results of a single HSC70
siRNA knockdown on Hut78 cells and
relabeling them to represent data from
Jurkat cells in Figure 6 in the first
submission of the JCI manuscript,
Figure 6 in JCI 2011, and Figure 10 in
R01 CA122737–01A2 (also included
as Slide 27 in the CREST
Presentation)
• reusing results for a second siRNA
construct that failed to knockdown
HSC70 in Jurkat cells and relabeling
them as from control samples in
Figure 6 in JCI 2011
Dr. Cruikshank entered into a
Voluntary Exclusion Agreement
(Agreement) and voluntarily agreed for
a period of five (5) years, beginning on
May 13, 2019:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility for or involvement
in nonprocurement programs of the
United States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376)
of OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’); and
(2) to exclude himself from serving in
any advisory capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2019–10874 Filed 5–23–19; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the joint meeting of the National Cancer
Advisory Board and NCI Board of
Scientific Advisors, June 10, 2018, 8:30
a.m. to June 11, 2018, 12:00 p.m.,
National Cancer Institute Shady Grove
Campus, Rockville, MD 20850 which
was published in the Federal Register
on February 11, 2019, 84 FR 3312.
This meeting notice is amended to
add two subcommittee meetings on
Sunday, June 9, 2019. The National
Cancer Advisory Board (NCAB) Ad Hoc
Subcommittee on Population Science,
Epidemiology and Disparities will meet
on June 9, 2019 from 5:30 p.m. to 7:00
p.m. and the NCAB Subcommittee on
Planning and Budget will meet on June
9, 2019 from 7:30 p.m. to 9:00 p.m. at
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
the Gaithersburg Marriott
Washingtonian Center, 9751
Washington Boulevard, Room—To Be
Determined, Gaithersburg, MD 20878.
This meeting notice is also amended
to change the meeting from a two-day to
a one-day meeting, correct the year, and
change the closed session agenda. The
joint meeting of the NCAB and NCI
Board of Scientific Advisors will now be
held on June 10, 2019 with the open
session from 8:30 a.m. to 4:45 p.m. and
the closed session from 5:00 p.m. to 6:00
p.m. The closed session agenda is
corrected to be the Review of NCAB
grant applications. The meeting is
partially Closed to the public.
Dated: May 21, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–10943 Filed 5–23–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be held as a
teleconference only and is open to the
public to dial-in for participation.
Individuals who plan to dial-in to the
meeting and need special assistance or
other reasonable accommodations in
order to do so, should notify the Contact
Person listed below in advance of the
meeting.
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee; Translational
Research Strategy Subcommittee (TRSS).
Date: June 19, 2019,
Time: 10:00 a.m. to 11:00 a.m.
Agenda: Review the Glioblastoma (GBM)
Working Group Report.
Place: National Cancer Institute Shady
Grove, Shady Grove, 9609 Medical Center
Drive, Rockville, MD 20850 (Telephone
Conference Call), Phone: 240–276–6500,
Conference Code: 1102766460, Passcode:
6460.
Contact Person: Peter Ujhazy, MD, Ph.D.,
Deputy Associate Director, Translational
Research Program, Division of Cancer
Treatment and Diagnosis, National Institutes
of Health, National Cancer Institute, 9609
Medical Center Drive, Room 3W106,
Rockville, MD 20850, 240–276–5681,
ujhazyp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
E:\FR\FM\24MYN1.SGM
24MYN1
]]>Agencies
[Federal Register Volume 84, Number 101 (Friday, May 24, 2019)]
[Notices]
[Page 24166]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10943]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the joint meeting of the
National Cancer Advisory Board and NCI Board of Scientific Advisors,
June 10, 2018, 8:30 a.m. to June 11, 2018, 12:00 p.m., National Cancer
Institute Shady Grove Campus, Rockville, MD 20850 which was published
in the Federal Register on February 11, 2019, 84 FR 3312.
This meeting notice is amended to add two subcommittee meetings on
Sunday, June 9, 2019. The National Cancer Advisory Board (NCAB) Ad Hoc
Subcommittee on Population Science, Epidemiology and Disparities will
meet on June 9, 2019 from 5:30 p.m. to 7:00 p.m. and the NCAB
Subcommittee on Planning and Budget will meet on June 9, 2019 from 7:30
p.m. to 9:00 p.m. at the Gaithersburg Marriott Washingtonian Center,
9751 Washington Boulevard, Room--To Be Determined, Gaithersburg, MD
20878.
This meeting notice is also amended to change the meeting from a
two-day to a one-day meeting, correct the year, and change the closed
session agenda. The joint meeting of the NCAB and NCI Board of
Scientific Advisors will now be held on June 10, 2019 with the open
session from 8:30 a.m. to 4:45 p.m. and the closed session from 5:00
p.m. to 6:00 p.m. The closed session agenda is corrected to be the
Review of NCAB grant applications. The meeting is partially Closed to
the public.
Dated: May 21, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-10943 Filed 5-23-19; 8:45 am]
BILLING CODE 4140-01-P
